Fig. 5: T_RM-like cells were CD8⁺T cells and exhibited T_RM phenotypes.

a Schematic of experimental design. On day 7 after the third tumor cell rechallenge, 3 × 10⁴ T_RM-containing brain-infiltrating lymphocytes (T_RM-BIL) from T-αFGL2–treated survivors were sorted by flow cytometry and co-inoculated i.c. along with 3 × 10³ DBT cells into naïve SCID mice; 35 days after transplantation, the SCID mice bearing transplanted T_RM-BILs were rechallenged with 3 × 10³ DBT cells i.c., combined with antibodies blocking CD8, CD4, or asGM1 i.p. b Kaplan-Meier survival curves of mice in (a) (n = 6 mice/group), log-rank test. c Kaplan–Meier survival curves of mice treated with anti-CD8, anti-CD4, or anti-asGM1 antibodies in (a) (n = 3 mice/group), log-rank test. The experiments were repeated twice with similar results. d Representative H&E staining of brains from c collected on day 14 after tumor cell rechallenge. Similar observations were made in three mice per group and representative images are shown. e Representative flow cytometry plots and graph showing ratio of CD69⁺CD103⁺ T cells, CD69⁺CD103⁻ T cells, and CD69⁺CD62L⁻ T cells in brain and PB of T-αFgl2-treated survivors (n = 4 for detection of CD69⁺CD103⁺ T cells and CD69⁺CD103⁻ T cells, n = 3 for detection of CD69⁺CD62L⁻ T cells; data represent mean ± SD), two-tailed t-test. The experiments were repeated twice with similar results.